Table 5.
Clinical drug development phase by therapeutic area that used molecular imaging
| Clinical drug development phase | Therapeutic area | |||||||
|---|---|---|---|---|---|---|---|---|
| Oncology | CNS | Cardiovascular | Gastrointestinal | Antibiotics | Others | Total | p value | |
| Phase 0 | 2 (2.0) | 1 (1.3) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 3 (1.4) | |
| Phase I | 66 (66.7) | 14 (18.4) | 3 (13.6) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 83 (39.9) | |
| Phase II | 27 (27.3) | 4 (5.3) | 11 (50.0) | 1 (33.3) | 0 (0.0) | 1 (20.0) | 44 (21.2) | |
| Phase III | 0 (0.0) | 4 (5.3) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 4 (1.9) | |
| Others | 1 (1.0) | 9 (11.8) | 1 (4.5) | 0 (0.0) | 0 (0.0) | 1 (20.0) | 12 (5.8) | |
| Unknown | 3 (3.0) | 44 (57.9) | 7 (31.8) | 2 (66.7) | 3 (100.0) | 3 (60.0) | 62 (29.8) | |
| Total | 99 (100.0) | 76 (100.0) | 22 (100.0) | 3 (100.0) | 3 (100.0) | 5 (100.0) | 208 (100.0) | < 0.0001 |
Frequency (column percentage) is shown
CNS, central nervous system